Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) EBIT: 2020-2024

Historic EBIT for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$176.3 million.

  • NewAmsterdam Pharma Co N.V's EBIT fell 120.55% to -$55.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.9 million, marking a year-over-year decrease of 10.21%. This contributed to the annual value of -$176.3 million for FY2024, which is 3.65% up from last year.
  • According to the latest figures from FY2024, NewAmsterdam Pharma Co N.V's EBIT is -$176.3 million, which was up 3.65% from -$183.0 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's EBIT's 5-year high stood at -$3.6 million during FY2022, with a 5-year trough of -$183.0 million in FY2023.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's EBIT had a median value of -$176.3 million in 2024 and averaged -$120.9 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 89.83% in 2022, then crashed by 5,043.86% in 2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's EBIT (Yearly) stood at -$6.2 million in 2020, then slumped by 464.26% to -$35.0 million in 2021, then soared by 89.83% to -$3.6 million in 2022, then plummeted by 5,043.86% to -$183.0 million in 2023, then rose by 3.65% to -$176.3 million in 2024.